Costimulatory and coinhibitory receptors in anti‐tumor immunity
- 21 April 2009
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 229 (1), 126-144
- https://doi.org/10.1111/j.1600-065x.2009.00771.x
Abstract
Summary: Despite the expression of antigens by tumor cells, spontaneous immune‐mediated rejection of cancer seems to be a rare event. T‐cell receptor engagement by peptide/major histocompatibility complexes constitutes the main signal for the activation of naive T cells but is not sufficient to initiate a productive generation and maintenance of effector cells. Full activation of T cells requires additional signals driven by costimulatory molecules present on activated antigen‐presenting cells but rarely on tumors. Following the discovery of B7‐1 (CD80), several other costimulatory molecules have been shown to contribute to T‐cell activation and have relevance for improving anti‐tumor immunity. Moreover, increasing the understanding of coinhibitory receptors has highlighted key additional pathways that can dominantly inhibit anti‐tumor T‐cell function. Improving positive costimulation, and interfering with negative regulation, continues to represent an attractive immunotherapeutic approach for the treatment of cancer. This review focuses upon those pathways with the highest potential for clinical application in human cancer patients.Keywords
This publication has 213 references indexed in Scilit:
- Immune regulation and control of regulatory T cells by OX40 and 4-1BBCytokine & Growth Factor Reviews, 2008
- Molecular regulation of T‐cell anergyEMBO Reports, 2008
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domainMolecular Immunology, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Generation and Characterization of B7-H4/B7S1/B7x-Deficient MiceMolecular and Cellular Biology, 2006
- B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survivalProceedings of the National Academy of Sciences of the United States of America, 2006
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic MelanomaJournal of Immunotherapy, 2006
- B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaThe Journal of Experimental Medicine, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003